VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

NCT07536100 | Not Yet Recruiting DMC

• 2 other identifiers: 031/2568IRB-IOD-031/2568
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.

Conditions

Androgenetic Alopecia (AGA)

Keywords

Androgenetic alopecia; Peptide hair serum; Minoxidil

Outcome Measures

Primary Outcomes (1)

• Change in hair density from baseline

  Change from baseline in hair count within a 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.

  12 and 24 weeks

Secondary Outcomes (5)

• Change in hair diameter and terminal hair count from baseline

  12 and 24 weeks

• Investigator Global Aesthetic Improvement Scale

  12 and 24 weeks

• Change in androgenetic alopecia severity

  12 and 24 weeks

• Patient Global Assessment of hair growth

  12 and 24 weeks

• Incidence of adverse events

  24 weeks

Study Arms (2)

VENEZE Peptide factor hair serum

EXPERIMENTAL

Participants in this arm will receive the VENEZE peptide factor hair serum applied topically to the scalp for 24 weeks.

Other: Veneze peptide hair serum

Topical 2% minoxidil solution

ACTIVE COMPARATOR

Participants in this arm will receive 2% minoxidil solution applied topically to the scalp for 24 weeks.

Drug: Topical minoxidil

Interventions

Topical minoxidil DRUG

Topical minoxidil solution applied to the scalp according to the study protocol for the treatment of androgenetic alopecia.

Also known as: Topical Minoxidil 2% solution

Topical 2% minoxidil solution

Veneze peptide hair serum OTHER

Participants will apply the VENEZE peptide factor hair serum to the affected scalp areas twice daily for 24 weeks according to the study protocol

Also known as: Hair growth peptide serum

VENEZE Peptide factor hair serum

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female participants aged ≥18 years.
• Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
• Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
• Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
• Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.
• Able to attend all scheduled visits during the 24-week study period.

You may not qualify if:

• Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
• History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
• Psychiatric disorders or other conditions that may affect participant safety or compliance.
• Pregnant or breastfeeding women.
• Diffuse hair thinning involving the occipital area.
• Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).
• History of hair transplantation at any time or hair extensions within 6 months prior to screening.
• Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.
• Use of light/laser therapy on the scalp within 3 months prior to screening.
• Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.
• Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.
• Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.
• Known hypersensitivity to study-related products or ingredients.
• Use of dutasteride within 12 months prior to screening.
• Use of systemic cytotoxic agents.

Sponsors & Collaborators

• Institute of Dermatology, Thailand: lead
• MEDEZE Cosmeceutical Company Limited: collaborator

Study Sites (1)

Institute of Dermatology

Bangkok, Thailand

Location

Related Publications (25)

• Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89. doi: 10.1016/s0190-9622(98)70007-6.

  PMID: 9777765 RESULT

• Lee YH,Choi HJ,Kim JY,Kim JE,Lee JH,Cho SH,Yun MY,An S,Song GY,Bae S

  RESULT

• Garza LA,Liu Y,Yang Z,Alagesan B,Lawson JA,Norberg SM,Loy DE,Zhao T,Blatt HB,Stanton DC,Carrasco L,Ahluwalia G,Fischer SM,FitzGerald GA,Cotsarelis G

  RESULT

• Wadstein J,Thom E,Gadzhigoroeva A

  RESULT

• Devjani S,Ezemma O,Kelley KJ,Stratton E,Senna M

  RESULT

• Bikash C

  RESULT

• Penha MA,Miot HA,Kasprzak M,Müller Ramos P

  RESULT

• Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007 Nov;57(5):767-74. doi: 10.1016/j.jaad.2007.04.012. Epub 2007 Aug 29.

  PMID: 17761356 RESULT

• Truong VL, Jeong WS. Hair growth-promoting mechanisms of red ginseng through Wnt/β-catenin. Plants (Basel). 2021;10(10):2067.

  RESULT

• Fang C, Chen Y, Zhao L, Huang Y, Li J, Xu Y, et al. Ginsenoside CK inhibits androgenetic alopecia by regulating dihydrotestosterone and Wnt/β-catenin in mice. Food Front. 2023;4(1):96-108.

  RESULT

• Jeong G, Kim H, Ahn J, Yoon J, Lee J, Cho AR, et al. Ginsenoside Re prevents catagen by activating autophagy and Wnt/β-catenin in human dermal papilla cells. Int J Mol Sci. 2022;23(9):4885.

  RESULT

• Zhang B, Zhang W, Luo J, He J, Zheng X, Zhu S, Rong B, Ai Y, Zhang L, He T. Effects of oleanolic acid on hair growth in mouse dorsal skin mediated via regulation of inflammatory cytokines. J Appl Biomed. 2023 Apr;21(1):48-57. doi: 10.32725/jab.2023.003. Epub 2023 Mar 27.

  PMID: 37016778 RESULT

• Huh S, Lee J, Jung E, Kim SC, Kang JI, Lee J, Kim YW, Sung YK, Kang HK, Park D. A cell-based system for screening hair growth-promoting agents. Arch Dermatol Res. 2009 Jun;301(5):381-5. doi: 10.1007/s00403-009-0931-0. Epub 2009 Mar 11.

  PMID: 19277688 RESULT

• Voiculescu VM, Raducan A, Popa LG, Cretu A, Draghici CC, Voinescu DC, et al. Comparative study of a topical and oral combination (Minoxicapil) in androgenetic alopecia: a 3-month clinical study. Cosmetics (Basel). 2025;12(4):152.

  RESULT

• Thom E, Thom EW. Lifestyle diseases and the hair growth cycle: a multidisciplinary approach using Nourkrin® with Marilex®, a proteoglycan replacement therapy, for anagen induction and maintenance. Ann Dermatol Res. 2017;1:6-11.

  RESULT

• Thom E, Wadstein J. Treating female diffuse hair loss using Nourkrin® Woman (with Marilex®) - an open-label, subjective, outcome study on hair growth and appearance, self-confidence and treatment satisfaction. J Clin Dermatol Ther. 2019;5:037.

  RESULT

• Couchman JR. Hair follicle proteoglycans. J Invest Dermatol. 1993 Jul;101(1 Suppl):60S-64S. doi: 10.1111/1523-1747.ep12362642.

  PMID: 8326155 RESULT

• Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004 Apr;50(4):541-53. doi: 10.1016/j.jaad.2003.06.014.

  PMID: 15034503 RESULT

• Shin HS, Park SY, Choi JS, Park JS, Lee JH. Promotion of hair growth by ginsenoside-Rb1 through dermal papilla cell proliferation and Wnt/β-catenin signaling. Phytother Res. 2014;28(12):1873-9.

  RESULT

• Harada N, Okajima K, Arai M, Kurihara H, Nakagata N. Administration of capsaicin and isoflavone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia. Growth Horm IGF Res. 2007 Oct;17(5):408-15. doi: 10.1016/j.ghir.2007.04.009. Epub 2007 Jun 13.

  PMID: 17569567 RESULT

• Pavithra TR, John J, Ramesh A, Narayanappa S. Comparative study of Procapil with platelet-rich plasma versus other adjuvant therapies in androgenetic alopecia. Cureus. 2023;15(4):e37493.

  RESULT

• Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, Dallob A, Vandormael K, Geissler L, Waldstreicher J. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999 Oct;41(4):550-4.

  PMID: 10495374 RESULT

• Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022 Nov;33(7):2946-2962. doi: 10.1080/09546634.2022.2109567. Epub 2022 Aug 15.

  PMID: 35920739 RESULT

• Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 2001 Sep;45(3 Suppl):S81-6. doi: 10.1067/mjd.2001.117428.

  PMID: 11511857 RESULT

• Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975 Nov;68(11):1359-65. doi: 10.1097/00007611-197511000-00009.

  PMID: 1188424 RESULT

MeSH Terms

Conditions

Alopecia

Interventions

Minoxidil; Solutions

Condition Hierarchy (Ancestors)

Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines; Pharmaceutical Preparations

Study Officials

• Chinmanat Lekhavat, MD, PhD

  Institute of Dermatology

  PRINCIPAL INVESTIGATOR

• Suchanaree Laitrakul, MD

  Institute of Dermatology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Chinmanat Lekhavat, MD, PhD

CONTACT

66023545222; chinmanat@inderm.org

Suchanaree Laitrakul, MD

CONTACT

66023545222

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief of Hair and Nail Center, Institute of Dermatology, Thailand

Model Details: Participants will be randomly assigned in a parallel-group design to receive either the peptide factor hair serum or 2% minoxidil solution for 24 weeks. Participants in each group will receive the assigned intervention throughout the study period. Efficacy outcomes and tolerability will be assessed and compared between the two groups.

Study Record Dates

• First Submitted: April 11, 2026
• First Posted: April 17, 2026
• Study Start: April 16, 2026
• Primary Completion (Estimated): November 30, 2026
• Study Completion (Estimated): November 30, 2026
• Last Updated: April 17, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

TH (1)